Profile

Unfortunately they were not able to provide any granular information regarding the percentage of patients who experienced ARRs at 1h/2h/3h/4h after the amivantamab dose. What our institution ended up doing just to be conservative was to start with 4h observation after C1D1 to align with the trial ...

Another one I forgot about on the east coast is DC lung on 10/10/2026: https://medstar.cloud-cme.com/course/courseoverview?P=0&EID=48248 Never been but heard great things - also only a one-day event on the weekend so won't need clinic/service coverage to attend :) ------------------------------ ...

Hi All, One thing I've struggled with recently is what meeting best caters to disease state specialists, as many of the conferences I historically attended have become increasingly less relevant to my daily practice. I had the opportunity to attend TTLC (targeted therapies in lung cancer) meeting a ...

Thank you all for your thoughts - I'm glad I'm not alone in struggling to define what the optimal observation time is for the first dose! I did reach out to the J&J MSL to see if they could provide a bit more granularity to rates of ARR based on observation time, specifically was it linear in nature ...

Hi All, I'm working through our institution's subcutaneous amivantamab treatment plan with it's recent approval and I wanted to see what everyone else's approach has been to post-C1D1 monitoring? Technically the package insert does not recommend any specific period of monitoring, however, there ...